

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

The table below sets forth the relevant operating data and indicators of the Group's owned hospitals by inpatients and outpatients for the three months (the second quarter) from April 1, 2026 to June 30, 2026 with comparative figures of the same period in 2025:

|                                                                                           | Three months from April 1 to June 30, |            |                      |
|-------------------------------------------------------------------------------------------|---------------------------------------|------------|----------------------|
|                                                                                           | 2026                                  | 2025       | Year-on-year changes |
| <b>Inpatients</b>                                                                         |                                       |            |                      |
| Number of inpatient bed-days                                                              | 961,729                               | 953,489    | 0.9%                 |
| Average inpatient spending per bed-day on treatment and general healthcare services (RMB) | 283                                   | 287        | -1.4%                |
| Average inpatient spending per bed-day on pharmaceutical sales (RMB)                      | 44                                    | 46         | -4.3%                |
| <b>Total average inpatient spending per bed-day (RMB) <sup>(1)</sup></b>                  | <b>327</b>                            | <b>333</b> | <b>-1.8%</b>         |
| <b>Outpatients</b>                                                                        |                                       |            |                      |
| Number of outpatient visits                                                               | 142,706                               | 174,224    | -18.1%               |
| Average outpatient spending per visit on treatment and general healthcare services (RMB)  | 88                                    | 80         | 10.0%                |
| Average outpatient spending per visit on pharmaceutical sales (RMB)                       | 215                                   | 198        | 8.6%                 |
| <b>Total average outpatient spending per visit (RMB)</b>                                  | <b>303</b>                            | <b>278</b> | <b>9.0%</b>          |

*Note:*

1. The above total average inpatient spending per bed-day is determined based on the Company's bills for services provided to patients, without taking into account differences with medical insurance settlements and the Company's income deduction for some medical expenses that may not be received.

The above operating data and indicators are based on the Company's records and have not been audited or reviewed by the Company's auditors. The operating data and indicators may be different from those disclosed in relevant periodical reports. The operating data and indicators disclosed in relevant periodical reports shall prevail if there is any discrepancy.

**Shareholders and potential investors of the Company are reminded to rationally deal with any information not officially released by the Company, and shareholders and potential investors of the Company should exercise caution when dealing in the shares of the Company.**

By order of the Board  
**Wenzhou Kangning Hospital Co., Ltd.**  
**GUAN Weili**  
*Chairman*

Zhejiang, the PRC  
July 3, 2026

*As at the date of this announcement, the Company's executive directors are Mr. GUAN Weili, Ms. WANG Lianyue and Mr. WANG Jian; the non-executive directors are Mr. QIN Hao and Mr. LI Changhao; and the independent non-executive directors are Ms. ZHONG Wentang, Ms. JIN Ling and Mr. SZETO Wing Fu.*